2月龄及7月龄至5岁儿童接种13价肺炎球菌结合疫苗基础免疫后的免疫持久性
本研究对既往完成试验用13价肺炎球菌结合疫苗(PCV13)全程接种的儿童随访5年,按年龄分为2月龄、7–11月龄、12–23月龄和2–5岁四组,检测13个血清型肺炎球菌抗体。各年龄组多数血清型抗体阳性率维持较高水平,几何平均浓度范围因年龄组而异,提示该疫苗在上述人群中具有良好的免疫持久性。
要点
- 2月龄组基础免疫后5年,除血清型3和4外,各血清型抗体阳性率均为100%。
- 7–11月龄组基础免疫后4年,除血清型3、4、6A和9V外,各血清型IgG浓度均≥0.35 μg/mL。
- 12–23月龄组和2–5岁组分别于基础免疫后3年和2年,除血清型3外IgG浓度均≥0.35 μg/mL。
核心结论
- PCV13应用于2月龄及7月龄至5岁人群具有良好的免疫持久性,为该疫苗的长期有效性提供了更广泛的证据。
研究设计与样本
- 对既往临床试验中完成试验用PCV13全程接种的儿童再次入组,排除接种其他肺炎球菌疫苗或入组前感染PCV13对应血清型肺炎链球菌者。
- 按年龄分为2月龄、7–11月龄、12–23月龄和2–5岁四组,分组与既往试验相同。
- 研究持续5年,在特定时间点检测PCV13所含13个血清型的肺炎球菌抗体,计算几何平均浓度(GMC)和血清阳性率(IgG浓度≥0.35 μg/mL的比例)。
主要发现
- 2月龄组基础免疫后5年,除血清型3和4外,血清阳性率均为100%;抗13个血清型IgG的GMC范围为0.733–15.160 μg/mL。
- 7–11月龄组基础免疫后4年,除血清型3、4、6A和9V外,所有参与者血清型特异性IgG浓度≥0.35 μg/mL;IgG GMC为0.753–11.031 μg/mL。
- 12–23月龄组基础免疫后3年,除血清型3外,所有参与者血清型特异性IgG浓度≥0.35 μg/mL;IgG GMC为0.815–13.111 μg/mL。
- 2–5岁组基础免疫后2年,除血清型3外,所有参与者血清型特异性IgG浓度≥0.35 μg/mL;IgG GMC为0.684–12.282 μg/mL。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pneumococcus is a common cause of pneumonia, meningitis, and other serious infections in children. The previous study has proved that the 13-valent pneumococcal conjugate vaccine (PCV13) has sufficient immunogenicity in children. The data on long-term persistence of immunity will help the follow-up development work of pneumococcal vaccines. METHODS: Children who received the full vaccination course of the tested PCV13 in the previous clinical trial were enrolled again, and these who received other pneumococcal vaccines, or were infected with one or more serotypes of S. pneumoniae corresponding to PCV13 before enrollment were excluded. Participants were divided into four groups by age which is same as that of previous trial. The study lasted for 5 years, during which we measured pneumococcal antibodies of 13 serotypes included in PCV13 at particular points in time. Geometric mean concentrations (GMCs) and seropositive rates (the rate of IgG concentration ≥0.35 μg/mL) of antibodies against 13 serotypes were calculated. RESULTS: For the participants aged 2 months, five years after primary vaccination, except for serotypes 3 and 4, seropositive rates were 100%. GMCs of IgG antibodies against 13 serotypes ranged from 0.733 to 15.160 μg/mL. All of the participants aged 7-11 months had the serotype-specific IgG concentration ≥0.35 μg/mL four years after primary vaccination with the exception of serotypes 3, 4, 6 A and 9 V. IgG GMCs were 0.753-11.031 μg/mL. All participants aged 12-23 months and 2-5 years old had the serotype-specific IgG concentration ≥0.35 μg/mL three or two years after primary vaccination respectively, except for serotype 3. IgG GMCs ranged from 0.815 to 13.111 μg/mL, and 0.684 to 12.282 μg/mL respectively. CONCLUSION: PCV13 was applied to the population aged 2 months and 7 months - 5 years old with a good immune persistence, providing more extensive evidence of long-term efficacy for that vaccine. TRIAL REGISTRATION: The trial was registered with ClinicalTrials.gov, number NCT06210737.
引用
- Li G, Ren T, Zhang H, et al. Persistence of immunity in children aged 2 months and 7 months - 5 years old after primary immunization with 13-valent pneumococcal conjugate vaccine. Vaccine. 2024. PMID: 39217777. doi:10.1016/j.vaccine.2024.126209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。